More data about ARASENS, applied to the european part of the study population

[Maxone73]

I would like to underline this part "The study is not about daro versus apa, versus... It's really early darolutamide versus a late AR pathway inhibitor. And the benefit is such that it confirms that even when you give docetaxel, an early introduction of the AR pathway inhibitor is critical for the survival of these patients."

Even if I admit that, given what I hear from people on other AT inhibitors and the related adverse effects, I am pretty happy I am on daro!

urotoday.com/video-lectures...